SPHK1 and metabolic dysfunction-associated steatotic liver disease: SphK2 is the main isoform of SphK in the liver, accounting for 90% of its total activity (33) Studies have shown that SphK2 drives the progression of non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) through dual mechanisms.